Clinical Study Details

Blood thinners remain a cornerstone in the treatment for Atrial Fibrillation.

Atrial fibrillation (also knowns as AFib), is a common type of cardiac arrhythmia, which refers to an irregular heartbeat rhythm. As a result, the heart cannot pump blood effectively which can lead to a variety of symptoms, including palpitations, shortness of breath, and fatigue.

Without management, Atrial Fibrillation can lead to formation of blood clots, increasing the risk of stroke, heart failure, and other heart-related complications. Many blood-thinner therapies are currently available, but the disadvantage is that they can increase the risk of bleeding.

AusTrials is conducting a study evaluating the effectiveness of a new blood thinner treatment intended to stop the formation of blood clots in people with atrial fibrillation, with a significantly reduced risk of bleeding.

You could be eligible to participate in the study if you:

• Are 18 years of age or older AND
• Suffer from Atrial Fibrillation

The study has a minimum duration of 3 months, with an expected duration of 2 years.

Eligible participants will be compensated for time and travel-related costs.

The study is being conducted in the following locations:

• Wellers Hill, QLD

Please contact AusTrials on 1300 190 841 for further information or follow the link below.